1. Home
  2. VIR vs MYGN Comparison

VIR vs MYGN Comparison

Compare VIR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIR
  • MYGN
  • Stock Information
  • Founded
  • VIR 2016
  • MYGN 1991
  • Country
  • VIR United States
  • MYGN United States
  • Employees
  • VIR N/A
  • MYGN N/A
  • Industry
  • VIR Biotechnology: Pharmaceutical Preparations
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • VIR Health Care
  • MYGN Health Care
  • Exchange
  • VIR Nasdaq
  • MYGN Nasdaq
  • Market Cap
  • VIR 844.9M
  • MYGN 744.7M
  • IPO Year
  • VIR 2019
  • MYGN 1995
  • Fundamental
  • Price
  • VIR $5.07
  • MYGN $4.46
  • Analyst Decision
  • VIR Strong Buy
  • MYGN Hold
  • Analyst Count
  • VIR 7
  • MYGN 16
  • Target Price
  • VIR $32.86
  • MYGN $15.47
  • AVG Volume (30 Days)
  • VIR 1.6M
  • MYGN 3.3M
  • Earning Date
  • VIR 05-07-2025
  • MYGN 05-06-2025
  • Dividend Yield
  • VIR N/A
  • MYGN N/A
  • EPS Growth
  • VIR N/A
  • MYGN N/A
  • EPS
  • VIR N/A
  • MYGN N/A
  • Revenue
  • VIR $20,861,000.00
  • MYGN $831,300,000.00
  • Revenue This Year
  • VIR N/A
  • MYGN N/A
  • Revenue Next Year
  • VIR $15.32
  • MYGN $6.42
  • P/E Ratio
  • VIR N/A
  • MYGN N/A
  • Revenue Growth
  • VIR N/A
  • MYGN 7.38
  • 52 Week Low
  • VIR $4.32
  • MYGN $3.81
  • 52 Week High
  • VIR $14.45
  • MYGN $29.30
  • Technical
  • Relative Strength Index (RSI)
  • VIR 47.79
  • MYGN 38.73
  • Support Level
  • VIR $4.72
  • MYGN $3.99
  • Resistance Level
  • VIR $5.24
  • MYGN $4.38
  • Average True Range (ATR)
  • VIR 0.32
  • MYGN 0.25
  • MACD
  • VIR 0.09
  • MYGN 0.17
  • Stochastic Oscillator
  • VIR 70.09
  • MYGN 91.55

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Share on Social Networks: